{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T21:07:46Z","timestamp":1781125666329,"version":"3.54.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.annder.2026.103470","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:09:51Z","timestamp":1772032191000},"page":"103470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gliptin- and immune checkpoint inhibitor-induced bullous pemphigoid: a real-life comparative study with idiopathic bullous pemphigoid"],"prefix":"10.1016","volume":"153","author":[{"given":"F.","family":"Gratteri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-7649","authenticated-orcid":false,"given":"J.","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alaibac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2026.103470_b0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1346-8138.16654","article-title":"What\u2019s new in the pathogeneses and triggering factors of bullous pemphigoid","volume":"50","author":"Ujiie","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2026.103470_b0010","first-page":"713","article-title":"S2k guideline for the diagnosis of pemphigus vulgaris\/foliaceus and bullous pemphigoid","volume":"13","author":"Schmidt","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.annder.2026.103470_b0015","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2026.103470_b0020","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamadermatol.2022.0354","article-title":"Risk factors for the development of bullous pemphigoid in US patients receiving immune checkpoint inhibitors","volume":"158","author":"Said","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2026.103470_b0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1203475420972349","article-title":"Gliptin-induced bullous pemphigoid: Canadian case series of 10 patients","volume":"25","author":"Armanious","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.annder.2026.103470_b0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2026.103470_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cllc.2023.10.007","article-title":"Lung cancer in women: the past, present, and future","volume":"25","author":"Florez","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annder.2026.103470_b0040","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annder.2026.103470_b0045","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2026.103470_b0050","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes","volume":"87","author":"Bur","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2026.103470_b0055","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2026.103470_b0060","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ddg.15638","article-title":"Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis","volume":"23","author":"Pruessmann","year":"2025","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963826000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963826000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:44:51Z","timestamp":1781124291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963826000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0151963826000049"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2026.103470","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gliptin- and immune checkpoint inhibitor-induced bullous pemphigoid: a real-life comparative study with idiopathic bullous pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2026.103470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103470"}}